Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

September 8, 2026 7:30 AM

Needham analyst Chad Messer reiterated a Buy rating and $86.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "Novartis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found